Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 14, 2025

Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause

View original at nasdaq.com
Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause The S&P 500 Index ($SPX) (SPY) on Friday closed down -0.05%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.65%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.06%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Further cuts in interest rates won't do much to patch over any cracks in the labor market but could have longer-lasting effects on inflation as commitment to 2% objective increasingly comes into question

    80% confidence

  • Recent pullback in DoorDash stock is a buying opportunity

    80% confidence

  • The October jobs report will be released without the unemployment rate

    80% confidence

  • It would be hard to support another rate cut unless there is convincing evidence that inflation is coming down faster than expectations or more than gradual cooling in labor market

    80% confidence

  • Paramount, Comcast, and Netflix are preparing to bid for Warner Bros Discovery

    80% confidence

  • The six-week government closure reduced real GDP growth in the current quarter by 1.5 percentage points, with more than half potentially recovered early next year

    80% confidence

  • 82% of reporting S&P 500 companies exceeded forecasts, on course for best quarter since 2021, with Q3 earnings up 14.6% vs expectations of 7.2%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stocks Settle Mixed as Fed Comments Suggest a Rate Cut Pause — Source | Via News | ViaNews EU